MOTS-c
MOTS-c Stability After Reconstitution: What Solution Data Can Show
JH
· 9 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 6 sections
There is no published, validated shelf life for MOTS-c in solution. What its sequence does tell you is where it is chemically vulnerable: two methionine residues and a tryptophan that can oxidise, and a strongly cationic, partly hydrophobic character that favours loss to container surfaces. A chromatogram showing unchanged purity after a period in the refrigerator addresses only some of that. It cannot establish sterility, retained content or biological activity, and it is not a shelf life.

General chemistry of dried and dissolved peptides is covered in lyophilised peptides and what degrades them. This page applies that chemistry to one sequence, and asks what a stability claim about MOTS-c in solution would have to contain to mean anything.
What is MOTS-c, chemically?
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA gene, first described in 2015 (Lee and colleagues, PMID 25738459). Its background as a research compound is in MOTS-c, the mitochondrial-derived peptide. For stability purposes, what matters is the sequence itself:
M R W Q E M G Y I F Y P R K L R
Reading it residue by residue is the quickest way to see which degradation routes apply and which do not.
| Feature in the sequence | Positions | Stability consequence |
|---|---|---|
| Methionine | 1, 6 | Oxidation to methionine sulfoxide; two sites means +16 and +32 Da products |
| Tryptophan | 3 | Oxidation, including light-induced; a further source of oxidised species |
| Tyrosine | 8, 11 | Oxidation-susceptible, more slowly; also give the peptide useful UV absorbance |
| Arginine and lysine | 2, 13, 14, 16 | Strong net positive charge at neutral pH; binding to negatively charged glass |
| Hydrophobic residues | W, I, F, Y, L | Combined with the charge, an amphipathic surface-active character |
| Glutamine (internal) | 4 | Deamidation possible but typically slow; not at the N-terminus, so no pyroglutamate route |
| Cysteine, asparagine | none | No disulfide scrambling; no fast asparagine deamidation |
That profile is quite different from many other research peptides. A sequence like BPC-157, with no oxidisable residues at all, faces a different set of risks. For MOTS-c, oxidation and surface loss are the two that a stability study cannot ignore.
Does MOTS-c oxidise in solution?
It has the residues that do. Methionine, cysteine, histidine, tryptophan and tyrosine are the amino acids most susceptible to oxidation in peptide and protein pharmaceuticals, and oxidation is driven by contaminating oxidants, catalysed by trace transition metals and induced by light, with pH, temperature and buffer composition also playing a part (Li and colleagues, PMID 18623513). MOTS-c carries four of those five residue types.
This is not merely theoretical for this peptide. When an anti-doping laboratory developed and validated a mass spectrometry method for MOTS-c in plasma, the final assay included two oxidation products of the peptide alongside four in-vitro metabolites (Knoop and colleagues, PMID 30394592). Oxidised MOTS-c is a real, measurable species that analysts found worth targeting.
Two analytical consequences follow.
Oxidised forms may or may not separate cleanly. Methionine sulfoxide is more polar than methionine, so oxidised species often elute slightly earlier on reversed-phase HPLC — but with two methionines, a tryptophan and possible combinations, partial co-elution with the main peak is plausible. A purity method that has not been shown to resolve these species can report an unchanged figure while oxidation proceeds.
Mass spectrometry sees them directly. A +16 Da shift per oxygen atom is easy to detect by LC-MS, which is why identity testing by mass is particularly informative for an oxidation-prone sequence. The respective strengths of the two methods are set out in HPLC and LC-MS in peptide testing.
Practical implications for storage are the general ones — protection from light, minimal headspace oxygen, clean containers free of metal contamination — but how much each matters for MOTS-c specifically is unmeasured in the published literature.
Can MOTS-c be lost from solution without degrading?
Yes, and this is the risk a purity figure is least able to reveal. MOTS-c has four basic residues and a free N-terminal amine against a single acidic residue, so it carries a substantial positive charge at neutral pH, alongside a run of hydrophobic side chains. That combination is the profile of peptides known to adsorb to surfaces.
The clearest demonstration comes from cationic membrane-active peptides: at typical experimental concentrations, 90 per cent or more of the peptide could be lost from solution to the walls of ordinary glass and plastic containers (Kristensen and colleagues, PMID 25932639). MOTS-c is not one of the peptides tested, and its behaviour has to be measured rather than inferred. But the mechanism — positive charge attracted to negatively charged glass, and hydrophobic contact with plastic — applies in principle, and it is most severe at low concentration, where a larger fraction of the total material sits at the surface.
The reason this matters for stability claims is arithmetic. A purity result is reported as area per cent: the main peak's share of everything the detector saw. Peptide stuck to a vial wall is not in the sample, so it is not in the denominator either. A solution can lose much of its MOTS-c to the container and still report the same purity. Only quantification against a reference standard, comparing measured concentration with the starting concentration, detects that loss. The same reasoning applies to aggregation at interfaces, discussed in does shaking damage peptides.
MOTS-c does have one analytical advantage here: its tryptophan and two tyrosines absorb at 280 nm, so its concentration can be estimated by UV absorbance using a calculated extinction coefficient. That is a reasonable check of content, though not of identity or purity.
What would a 30-day chromatogram actually establish?
Suppose a supplier or forum post shows two HPLC traces of a MOTS-c solution, one at preparation and one after some weeks refrigerated, with similar purity. Here is what that does and does not support.
| Question | Does the comparison answer it? |
|---|---|
| Did new UV-absorbing impurities appear above the method's detection limit? | Partly — if the method resolves the relevant degradants |
| Did methionine or tryptophan oxidise? | Only if the method was shown to separate oxidised forms, or LC-MS was used |
| Is the concentration unchanged? | No — area-per-cent purity does not measure content |
| Was peptide lost to the container? | No |
| Is the solution sterile? | No — chromatography does not detect microorganisms |
| Is the peptide still biologically active? | No — purity is not a functional assay |
| Does this apply to another lot, diluent or container? | No |
| Is this a shelf life? | No |
A single pair of traces is an observation about one vial. Turning it into a stability claim would need a written protocol fixed in advance: defined solution composition, pH and container; storage conditions with temperature records; several replicate preparations; samples pulled at set intervals; a method demonstrated to be stability-indicating by forced degradation — deliberately oxidising, heating and light-stressing MOTS-c to prove the method resolves the products; quantitative content against a reference standard; and acceptance criteria stated before the first sample was analysed. The general requirements of a stability-indicating method — separation of all degradation products and establishment of mass balance among them — are reviewed by Bakshi and Singh (PMID 12049968).
None of that has been published for MOTS-c in a laboratory diluent, and this page states no number of days as acceptable. Note too that "stability" in the MOTS-c literature often means something else: the doping-control work evaluated stability of the peptide in plasma samples and its in-vitro metabolism (Knoop and colleagues, PMID 30394592), which is a question about biological matrices, not about a vial.
Does the diluent change MOTS-c stability?
It can, but in ways that have not been characterised for this peptide. The preservative in bacteriostatic water suppresses microbial growth and has no effect on oxidation or adsorption. Its own limits — including why the 28-day multiple-dose convention does not transfer to a dissolved peptide — are discussed in bacteriostatic water and the 28-day rule. pH affects oxidation rates and the peptide's net charge, and therefore adsorption, but no published work maps those effects for MOTS-c.
The concentration calculator does the one piece of arithmetic this site supports — mass over volume — and nothing further follows from it.
Supplied here for laboratory use: MOTS-c. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
How long is MOTS-c stable after reconstitution? No validated answer exists. No published stability programme has measured MOTS-c in a laboratory diluent with a stability-indicating method, replicates and pre-set acceptance criteria. Any specific number of days quoted online comes from something less than that, typically a single chromatogram. The honest position is that solution stability for this peptide is unestablished.
Why does MOTS-c's sequence matter for storage? It decides which degradation routes apply. MOTS-c has two methionines and a tryptophan, which can oxidise, and four basic residues alongside several hydrophobic ones, which favour adsorption to containers. It has no cysteine or asparagine. A stability study for MOTS-c therefore has to look specifically for oxidation and for loss of content.
Can HPLC purity show whether MOTS-c has oxidised? Only if the method has been shown to resolve the oxidised forms from intact peptide. Oxidised species are more polar and often elute earlier, but partial overlap is possible with several oxidisable residues. LC-MS detects oxidation directly as a mass increase of 16 daltons per oxygen atom, which makes it the stronger tool for this question.
Does unchanged purity mean the concentration is unchanged? No. Purity is a ratio of peaks within the sample analysed. Peptide that has adsorbed to the vial wall or precipitated and been filtered out is simply absent from that sample, so purity can stay the same while the amount in solution falls. Concentration must be measured separately against a reference standard or by UV absorbance.
Does refrigeration make a MOTS-c solution sterile or stable? Neither. Cold storage slows chemical reactions and microbial growth, but it does not kill organisms already present and does not stop oxidation or adsorption. Sterility depends on how the solution was prepared and handled; chemical stability has to be measured. Refrigeration is a reasonable storage condition, not evidence of anything.
Selected Research References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. pubmed.ncbi.nlm.nih.gov/25738459
- Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry. 2019;33(4):371-380. pubmed.ncbi.nlm.nih.gov/30394592
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnology and Bioengineering. 1995;48(5):490-500. pubmed.ncbi.nlm.nih.gov/18623513
- Kristensen K, Henriksen JR, Andresen TL. Adsorption of cationic peptides to solid surfaces of glass and plastic. PLoS One. 2015;10(5):e0122419. pubmed.ncbi.nlm.nih.gov/25932639
- Bakshi M, Singh S. Development of validated stability-indicating assay methods: critical review. Journal of Pharmaceutical and Biomedical Analysis. 2002;28(6):1011-1040. pubmed.ncbi.nlm.nih.gov/12049968
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
